The Fly | NYXH

Leadless & Battery-Free Design: The Genio system is the only hypoglossal nerve stimulation device that is leadless and does not require an implanted battery, reducing the need for future battery replacement surgeries and simplifying the device.

Minimally Invasive Implantation: The therapy involves a single, submental (under the chin) incision for implantation, which is generally less complex than multi-incisional approaches used by competitors.

Unilateral Stimulation Approach: Nyxoah's Genio system offers unilateral hypoglossal nerve stimulation, providing a distinct alternative to bilateral stimulation systems and potentially appealing to a different patient or physician preference.

Regulatory Approval and Market Access Delays: Failure to obtain or delays in obtaining necessary regulatory approvals (e.g., FDA PMA) in key markets, or difficulties in securing favorable reimbursement policies from payers, could significantly impede commercialization and revenue generation.

Intense Competition in OSA Treatment Market: Nyxoah faces significant competition from established treatments like CPAP, alternative surgical options, and other neurostimulation devices (e.g., Inspire Medical), which could limit market share and pricing power for their Genio system.

Limited Market Adoption and Reimbursement Coverage: Even with regulatory approval, there's a risk that the Genio system may not achieve broad market acceptance among physicians and patients, or may not secure adequate and timely reimbursement from third-party payers, hindering sales growth.